PMID- 29369971
OWN - NLM
STAT- MEDLINE
DCOM- 20181011
LR  - 20211204
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 102
IP  - 2S Suppl 1
DP  - 2018 Feb
TI  - mTOR Inhibition and Clinical Transplantation: Heart.
PG  - S27-S29
LID - 10.1097/TP.0000000000001921 [doi]
AB  - This brief overview discusses recent data on the use of mammalian target of 
      rapamycin (mTOR) inhibitors in heart transplantation. Trials on de novo use have 
      shown good efficacy of mTOR inhibitors; however, adverse events are often seen. 
      Conversion protocols in long-term patients are mainly used in patients with renal 
      insufficiency. Calcineurin inhibitor minimization and conversion to calcineurin 
      inhibitor-free protocols have proven to stabilize renal function in recent 
      trials. Lastly, beneficial effects of mTORs against the development of graft 
      vasculopathy, cytomeglovirus infection and malignancy have been shown. 
      Nevertheless, lower tolerability of the drug has affected the long-term use in 
      patients. Future consideration of using mTORs will be individualized protocols in 
      special subpopulation after heart transplantation.
FAU - Zuckermann, Andreas
AU  - Zuckermann A
AD  - Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
FAU - Osorio-Jaramillo, Emilio
AU  - Osorio-Jaramillo E
AD  - Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
FAU - Aliabadi-Zuckermann, Arezu Zejnab
AU  - Aliabadi-Zuckermann AZ
AD  - Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Calcineurin Inhibitors)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
EIN - Transplantation. 2018 Jul;102(7):e358. Osorio-Jamillio, Emilio [corrected to 
      Osorio-Jaramillo, Emilio]. PMID: 29952927
MH  - Calcineurin Inhibitors/therapeutic use
MH  - Drug Therapy, Combination
MH  - Everolimus/*therapeutic use
MH  - Graft Rejection/*prevention & control
MH  - *Heart Transplantation
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Postoperative Complications/prevention & control
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Sirolimus/*therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Treatment Outcome
EDAT- 2018/01/26 06:00
MHDA- 2018/10/12 06:00
CRDT- 2018/01/26 06:00
PHST- 2018/01/26 06:00 [entrez]
PHST- 2018/01/26 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
AID - 00007890-201802001-00005 [pii]
AID - 10.1097/TP.0000000000001921 [doi]
PST - ppublish
SO  - Transplantation. 2018 Feb;102(2S Suppl 1):S27-S29. doi: 
      10.1097/TP.0000000000001921.